{
    "clinical_study": {
        "@rank": "112856", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the effect of a new von Willebrand factor concentrate on bleeding\n      time, in vivo recovery, and circulating half-life of the infused factor in patients with von\n      Willebrand's disease.\n\n      II.  Assess the safety of von Willebrand factor in these patients."
        }, 
        "brief_title": "Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease", 
        "condition": "Von Willebrand's Disease", 
        "condition_browse": {
            "mesh_term": "Von Willebrand Diseases"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate.  Timed blood\n      studies are performed for the next 96 hours.\n\n      Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n          -  von Willebrand's disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004667", 
            "org_study_id": "199/11955", 
            "secondary_id": "UNCCH-826"
        }, 
        "intervention": {
            "intervention_name": "von Willebrand factor", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "hematologic disorders", 
            "rare disease", 
            "von Willebrand's disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Gilbert C. White", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8826903", 
            "citation": "Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, Thompson AR, White GC 2nd. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol. 1996 Sep;94(4):740-5."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004667"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of North Carolina", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1993", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}